Ray Co

Ray Co Equity Growth

The Year-over-Year Equity Growth of Ray Co (228670.KQ) as of Nov 18, 2026 is 4.26 %. In the previous year, Year-over-Year Equity Growth was -42.35 % — a change of -110.05% (higher).

Equity Growth

4.26 %

YoY

-110.05%

Last updated:

Year-over-Year Equity Growth of Ray Co is 2025 4.26 % . Year-over-Year Equity Growth of Ray Co was 2024 -42.35 % . It decreases by -110.05% higher compared to the previous year.

The Ray Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
78.86 KRW
Jan 1, 2019
118.95 KRW
Jan 1, 2020
13.48 KRW
Jan 1, 2021
54.26 KRW
Jan 1, 2022
15.48 KRW
Jan 1, 2023
9.43 KRW
Jan 1, 2024
-42.35 KRW
Jan 1, 2025
4.26 KRW
The Ray Co Equity Growth history
YEAREquity GrowthYoY
4.26 %-110.05%
-42.35 %-549.16%
9.43 %-39.10%
15.48 %-71.47%
54.26 %+302.47%
13.48 %-88.67%
118.95 %+50.83%
78.86 %+724.91%
9.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ray Co Stock analysis

What does Ray Co do? Ray Co., Ltd. generates revenue through the manufacturing and sale of advanced technology medical devices, focusing on digital diagnostic systems and digital therapy solutions. The company produces dental radiography equipment such as x-ray systems and cone beam computed tomography (CBCT) systems, alongside 3D scanning, dental computer aided design (CAD), and 3D printers for prosthodontics, orthodontics, and implant surgery. Domestic and overseas markets purchase these products, with the company operating through subsidiaries to distribute its offerings globally. Digital diagnostic systems like dental radiography equipment and CBCT systems are sold to healthcare providers and dental clinics, while digital therapy solutions including 3D scanning and CAD systems target dental laboratories and surgical centers. The firm's product portfolio serves both domestic and international clients, leveraging its subsidiaries for global distribution channels. Ray Co., Ltd. emphasizes advanced technology in its medical device offerings, with digital therapy solutions such as 3D printers and CAD systems being key revenue drivers. The company's focus on dental-specific applications ensures targeted sales to specialized healthcare segments, including prosthodontics, orthodontics, and implant surgery practices. Ray Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ray Co stock

Year-over-Year Equity Growth of Ray Co is 4.26 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Ray Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Ray Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Ray Co

All Key Metrics — Ray Co